Growing Diagnostics SeraCare operates under the LGC Diagnostics & Genomics brand, signaling strong distributor and market access partnerships that can facilitate co-selling, channel expansion, and bundled offerings for clinical diagnostics and quality control products.

Expanded QC Portfolio Recent launches of ACCURUN Babesia Positive Molecular Control Kit, AccuSeries HEV Performance Panel, and AccuPlex SARS-CoV-2 panels indicate a broad and growing quality control and reference material portfolio ideal for partnerships with diagnostic labs, CROs, and assay developers seeking robust QC solutions.

SARS-CoV-2 Leadership A history of SARS-CoV-2 quality solutions and panels positions SeraCare as a trusted partner for assay developers and manufacturers pushing new variants and antigen/antibody tests, offering opportunities for collaboration on validation, performance panels, and reference materials.

Global Patient Samples Their global patient samples program, launched in collaboration with a major European reference lab, presents opportunities to co-develop or source remnant samples for assay validation, regulatory submissions, and external quality assessment programs.

Mid-market Focus With revenue in the 50 to 100 million range and 51-200 employees, SeraCare sits between mid-market players and larger suppliers, offering potential for recurring revenue through managed QC services, subscription access to control materials, and tiered partnership programs.